Online Only Articles

Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program

The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, UK
Janssen EU HEMAR Statistics & Modeling, Beerse, Belgium
Janssen-Cilag EMEA Medical Affairs, Dublin, Ireland
Janssen Pharmaceuticals, Paris, France
Janssen-Cilag EMEA Medical Affairs, Sollentuna, Sweden
Janssen Research & Development, Raritan, NJ, USA
Vol. 103 No. 5 (2018): May, 2018 https://doi.org/10.3324/haematol.2017.178798